Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Chakravarty

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
The Lancet. Rheumatology|January 30, 2024
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studiesPhilip J Mease, Philip S Helliwell, Dafna D Gladman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
RMD Open|February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experiencedChristopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Cancer Research|September 27, 2017
PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4<sup>+</sup> TILs in the Presence of PD-L1<sup>+</sup> TAMsAustin K Mattox, Jina Lee, William H Westra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practiceC B Westphalen, L Boscolo Bielo, P Aftimos, et al.
Seminars in Arthritis and Rheumatism|February 4, 2024
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generationRachael A Gordon, Yann Nguyen, Nathan Foulquier, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
The Lancet. Rheumatology|January 30, 2024
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studiesPhilip J Mease, Philip S Helliwell, Dafna D Gladman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Oncologist use and perception of large panel next-generation tumor sequencingA M Schram, D Reales, J Galle, et al.
RMD Open|February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experiencedChristopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Cancer Research|September 27, 2017
PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4<sup>+</sup> TILs in the Presence of PD-L1<sup>+</sup> TAMsAustin K Mattox, Jina Lee, William H Westra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancersJ van de Haar, P Roepman, F Andre, et al.
BMJ Open|December 23, 2022
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trialRebecca H Haberman, Katrina A MacFarlane, Sydney Catron, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2025
ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practiceC B Westphalen, L Boscolo Bielo, P Aftimos, et al.
Seminars in Arthritis and Rheumatism|February 4, 2024
The Sjögren's Working Group: The 2023 OMERACT meeting and provisional domain generationRachael A Gordon, Yann Nguyen, Nathan Foulquier, et al.
Pageof 10